Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | F10 | P00742 | 4/20 | 0.32 |
| ▸ | F2 | P00734 | 4/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20475329 | 0.91 | MAPT (0.41) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL20475355 | 0.85 | MAPT (0.39) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL15548874 | 0.83 | MAPT (0.40) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL20475270 | 0.82 | F10 (0.43) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL1269119 | 0.82 | F10 (0.43) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL1269176 | 0.81 | MAPT (0.46) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL20475361 | 0.81 | MAPT (0.46) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL20475336 | 0.80 | KDM4E (0.41) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL18640911 | 0.78 | ALDH1A1 (0.38) | MAPTKDM4ELMNAALDH1A1F10 | |
| SCHEMBL20475388 | 0.78 | KDM4E (0.44) | MAPTKDM4ELMNAALDH1A1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518754-B2 | Radiolabeled pharmaceuticals and methods of making and using same | YALE UNIVERSITY (US) | 2022-12-06 | — | — | US | disclosed |
| WO-2018152339-A1 | RADIOLABELED PHARMACEUTICALS AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2018-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518754-B2 | Radiolabeled pharmaceuticals and methods of making and using same | SLC18A2, SLC18A3, SLC1A2 | MAPT 200/4885KDM4E 1686/4885LMNA 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.